

- M. A. Barradas, J. Y. Jeremey, G. J. Kontoghiorghes, D. P. Mikhailidis, A. V. Hoffbrand, and P. Dandona. Iron chelators inhibit human platelet aggregation, thromboxane A2 synthesis and lipoxygenase activity. *FEBS Lett.* 245 (1,2):105-109, 1989.
- Maria Stearns. Drug for Iron Overload Passes Major Safety Hurdle; May Benefit Patients with Thalassemia and Other Blood Disorders. *1995-2000 ScienceDaily Magazine*.
- Nancy F. Olivieri and Gary M. Brittenham. Long-Term Trials of Deferiprone in Cooley's Anemia. *The Departments of Medicine and Pediatrics The Hospital for Sick Children, Division of Hematology, University of Toronto, Canada (N.F.O.)* Sep. 27, 1999.
- N. F. Olivieri and G. Brittenham. Long-Term Trials of Deferiprone in Cooley's Anemia. *Ann.N.Y.Acad.Sci.* 80:217-222, 1998.
- Kontoghiorghes GJ, Aldouri MA, Sheppard L, Hoffbrand AV. 1,2-Dimethyl-3-hydroxypyrid-4-one, an orally active chelator for treatment of iron overload. *Lancet.* Jun. 6, 1987;1(8545):1294-5.
- Nathan DG. An orally active iron chelator. *N Engl J Med.* Apr. 6, 1995;332(14):953-4.
- Olivieri NF, Brittenham GM, Matsui D, Berkovitch M, Blendis LM, Cameron RG, McClelland RA, Liu PP, Templeton DM, Koren G. Iron-chelation therapy with oral deferoxiprone in patients with thalassemia major. *N Engl J Med.* Apr. 6, 1995;332(14):918-22.
- Biochimica et biophysica acta molecular basis of disease. v1500 n3 (Mar. 17, 2000) : p. 342-348. (Please note this reference is the same as *Biochimica et biophysica acta molecular basis of disease*; V.1500; No. 3; Mar. 17, 2000; pp. 342-348—(Reference 59)).
- Cohen AR, Martin MB. Iron chelation with oral deferoxiprone in patients with thalassemia. *N Engl J Med.* Dec. 3, 1998;339(23):1713-4.
- Grady RW, Giardina PJ. Iron chelation with oral deferoxiprone in patients with thalassemia. *N Engl J Med.* Dec. 3, 1998;339(23):1712-3.
- Wonke B, Telfer P, Hoffbrand AV. Iron chelation with oral deferoxiprone in patients with thalassemia. *N Engl J Med.* Dec. 3, 1998;339(23):1712.
- Stella M, Pinzello G, Maggio A. Iron chelation with oral deferoxiprone in patients with thalassemia. *N Engl J Med.* Dec. 3, 1998;339(23):1712.
- Callea F. Iron chelation with oral deferoxiprone in patients with thalassemia. *N Engl J Med.* Dec. 3, 1998;339(23):1710-1.
- Tricca F, Spino M. Iron chelation with oral deferoxiprone in patients with thalassemia. *N Engl J Med.* Dec. 3, 1998;339(23):1710.
- Hershko C., Link G., and Ioav C.. Pathophysiology of Iron Overload. *Ann.N.Y.Acad.Sci.* 850:191-201, 1998.
- Mumby, S., Chaturvedi, R.R., Brierley, J., Lincoln, C., Petros, A., Redington, A.N., Gutteridge, J.M.C.. Iron overload in paediatrics undergoing cardiopulmonary bypass. *Biochimica et biophysica acta molecular basis of disease:* v1500 n3 (Mar. 17, 2000): p. 342-348.
- Y. Tung, F. J. Farrell, T. M. McCashland, R. G. Gish, B. R. Bacon, E. B. Keeffe, and K. V. Kowdley. Long-term follow-up after liver transplantation in patients with hepatic iron overload. *Liver Transpl.Surg.* 5:369-374, 1999.
- Telfer PT, Prescott E, Hoden S, Walker M, Hoffbrand AV, Wonke B. Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major [In Process Citation]. *Br J Haematol* 2000; 110(4):971-977.
- Wonke B, Anderson L, Pennell D.J. Iron Chelation Treatment Based on Magnetic Resonance Imaging (MRI) in B-Thalassaemia Major. [Abstract] 11<sup>th</sup> International Conference on Oral Chelation, Catania, Italy, pp. 61-65, 2001.
- Diav-Citrin et al., 1997, Oral iron chelation with Deferiprone, *Clinics of North America*, (Feb. 1997) 44 (1) 235-47. Ref. 75,XP001030553.
- Gabriella Link et al., Cardioprotective effect of  $\alpha$ -tocopherol, ascorbate, deferoxamine, and deferoxiprone: Mitochondrial function in cultured, iron-loaded heart cells, *J. Lab Clin. Med.*, 133(2), p. 179-183 (1999).
- B. Wonke et al., Combined Therapy with Deferiprone and Desferrioxamine, *British Journal of Haematology*, 103, p. 361-183 (1998).
- Orna Diav-Citrin et al., Oral Iron Chelation with Deferprone, *New Frontiers in Pediatric Drug Therapy*, 44(1) p. 235-247 (1997).

\* cited by examiner